# MSTN

## Overview
The MSTN gene encodes the myostatin protein, a member of the transforming growth factor-beta (TGF-β) superfamily, which functions as a critical regulator of muscle growth. Myostatin is categorized as a secreted growth differentiation factor that primarily acts as a negative regulator of skeletal muscle mass. The protein is synthesized as a precursor that undergoes proteolytic processing to yield a mature, biologically active form, which functions as a disulfide-linked dimer (Lee2016Myostatin; Wolfman2003Activation). Myostatin exerts its effects by binding to activin type II receptors, initiating a signaling cascade that involves Smad proteins, ultimately leading to the inhibition of myoblast proliferation and differentiation (Rodriguez2014Myostatin). The regulation of myostatin activity is complex, involving interactions with various proteins such as follistatin and GASP-1, which modulate its inhibitory effects on muscle growth (Lee2010Extracellular). Mutations or alterations in the MSTN gene can lead to significant physiological changes, including muscle hypertrophy, and have been implicated in various clinical conditions (Schuelke2004Myostatin; Matika2019Balancing).

## Structure
The myostatin protein, encoded by the MSTN gene, is a member of the transforming growth factor-beta (TGF-β) superfamily. Its primary structure consists of a precursor protein that undergoes proteolytic processing to produce a mature, active form. The precursor includes a signal sequence, an N-terminal propeptide domain, and a C-terminal mature domain (Lee2016Myostatin). The secondary structure of myostatin features characteristic TGF-β folds, which are common in this protein family (Wolfman2003Activation).

In its quaternary structure, myostatin forms a disulfide-linked dimer, which is the biologically active form of the protein (Wolfman2003Activation). This dimerization is crucial for its function as a negative regulator of muscle growth. The myostatin protein also undergoes post-translational modifications, including glycosylation, which may influence its stability and activity (Singh2014Molecular).

The myostatin protein structure includes specific domains such as an N-terminal secretory signal, a propeptide region, and a mature peptide region. Key features include a proteolysis cleavage motif, nine cysteine residues in the mature peptide, and two glycosylation sites (Singh2014Molecular). These structural elements are essential for its regulatory role in muscle growth.

## Function
Myostatin, encoded by the MSTN gene, is a critical regulator of muscle growth in humans. It functions primarily as a negative regulator of myoblast proliferation and differentiation, maintaining muscle mass homeostasis. Myostatin achieves this by inhibiting the cell cycle progression of myoblasts, specifically arresting them in the G1 phase, which prevents their transition to the S phase. This is mediated through the upregulation of the cyclin-dependent kinase inhibitor p21, leading to decreased activity of cdk2 and reduced phosphorylation of the retinoblastoma protein (pRb) (Thomas2000Myostatin; McFarlane2011Human).

In addition to its role in cell cycle regulation, myostatin also inhibits myogenic differentiation by downregulating key myogenic regulatory factors such as MyoD and myogenin. This inhibition is associated with the activation of Smad3 signaling and the Notch signaling pathway, which further suppresses myotube formation and reduces the myotube fusion index (McFarlane2011Human). Myostatin's activity is primarily localized to skeletal muscle tissue, where it acts through an autocrine mechanism to regulate muscle growth and differentiation (Rı́os2002Myostatin). These molecular processes underscore myostatin's essential role in controlling muscle development and regeneration.

## Clinical Significance
Mutations in the MSTN gene, which encodes myostatin, can lead to significant physiological changes, particularly muscle hypertrophy. In humans, a specific mutation in the MSTN gene has been associated with gross muscle hypertrophy, as observed in a child with extraordinary muscle development and normal motor and mental function (Schuelke2004Myostatin). This mutation results in a misspliced mRNA and a truncated protein, leading to the absence of functional myostatin and increased muscle mass (Schuelke2004Myostatin).

In animals, similar mutations have been linked to the "double muscling" phenotype in cattle, such as Belgian Blue and Piedmontese breeds, where mutations cause a loss of function in the myostatin protein, resulting in increased muscle mass and reduced fat (McPherron1997Double). In pigs, a premature stop mutation in the MSTN gene is associated with increased muscle depth and reduced fat depth, although it also leads to a recessive leg weakness syndrome (Matika2019Balancing).

Alterations in myostatin expression levels are also clinically significant. Elevated myostatin levels are associated with conditions like osteoarthritis, where they correlate with disease severity, and diabetes, where increased expression is linked to impaired insulin sensitivity and obesity (Omosule2021Deciphering).

## Interactions
Myostatin (MSTN) interacts with several proteins that regulate its activity and influence muscle growth. MSTN binds to activin type II receptors, primarily ACVR2B, which then activate type I receptors (ALK4 and ALK5), leading to the phosphorylation of Smad2 and Smad3. These phosphorylated Smads form a complex with Smad4, translocate to the nucleus, and activate target gene transcription (Rodriguez2014Myostatin).

Follistatin is a potent inhibitor of MSTN, capable of blocking its activity and promoting muscle growth. Overexpression of follistatin in skeletal muscle significantly increases muscle mass, mimicking the effects of MSTN loss-of-function mutations (Lee2010Extracellular). FSTL-3, similar to follistatin, also inhibits MSTN by binding to it, leading to increased muscle mass in transgenic models (Lee2010Extracellular).

GASP-1 and GASP-2 are other MSTN binding proteins. GASP-1 can bind directly to the MSTN C-terminal dimer and inhibit its activity, as well as bind the MSTN propeptide and inhibit the related protein GDF-11/BMP-11 (Lee2010Extracellular). These interactions highlight the complex regulatory network involving MSTN and its role in muscle mass regulation.


## References


[1. (Lee2016Myostatin) Sang Beum Lee, Jeong Hwan Kim, Deuk-Hee Jin, Hyung-Joo Jin, and Yong Soo Kim. Myostatin inhibitory region of fish (paralichthys olivaceus) myostatin-1 propeptide. Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 194–195:65–70, April 2016. URL: http://dx.doi.org/10.1016/j.cbpb.2016.01.010, doi:10.1016/j.cbpb.2016.01.010. This article has 9 citations.](https://doi.org/10.1016/j.cbpb.2016.01.010)

[2. (Schuelke2004Myostatin) Markus Schuelke, Kathryn R. Wagner, Leslie E. Stolz, Christoph Hübner, Thomas Riebel, Wolfgang Kömen, Thomas Braun, James F. Tobin, and Se-Jin Lee. Myostatin mutation associated with gross muscle hypertrophy in a child. New England Journal of Medicine, 350(26):2682–2688, June 2004. URL: http://dx.doi.org/10.1056/nejmoa040933, doi:10.1056/nejmoa040933. This article has 1060 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1056/nejmoa040933)

[3. (Matika2019Balancing) Oswald Matika, Diego Robledo, Ricardo Pong-Wong, Stephen C. Bishop, Valentina Riggio, Heather Finlayson, Natalie R. Lowe, Annabelle E. Hoste, Grant A. Walling, Jorge del-Pozo, Alan L. Archibald, John A. Woolliams, and Ross D. Houston. Balancing selection at a premature stop mutation in the myostatin gene underlies a recessive leg weakness syndrome in pigs. PLOS Genetics, 15(1):e1007759, January 2019. URL: http://dx.doi.org/10.1371/journal.pgen.1007759, doi:10.1371/journal.pgen.1007759. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1371/journal.pgen.1007759)

[4. (McFarlane2011Human) Craig McFarlane, Gu Zi Hui, Wong Zhi Wei Amanda, Hiu Yeung Lau, Sudarsanareddy Lokireddy, Ge XiaoJia, Vincent Mouly, Gillian Butler-Browne, Peter D. Gluckman, Mridula Sharma, and Ravi Kambadur. Human myostatin negatively regulates human myoblast growth and differentiation. American Journal of Physiology-Cell Physiology, 301(1):C195–C203, July 2011. URL: http://dx.doi.org/10.1152/ajpcell.00012.2011, doi:10.1152/ajpcell.00012.2011. This article has 84 citations.](https://doi.org/10.1152/ajpcell.00012.2011)

[5. (Omosule2021Deciphering) Catherine L. Omosule and Charlotte L. Phillips. Deciphering myostatin’s regulatory, metabolic, and developmental influence in skeletal diseases. Frontiers in Genetics, March 2021. URL: http://dx.doi.org/10.3389/fgene.2021.662908, doi:10.3389/fgene.2021.662908. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fgene.2021.662908)

[6. (Rodriguez2014Myostatin) J. Rodriguez, B. Vernus, I. Chelh, I. Cassar-Malek, J. C. Gabillard, A. Hadj Sassi, I. Seiliez, B. Picard, and A. Bonnieu. Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways. Cellular and Molecular Life Sciences, 71(22):4361–4371, July 2014. URL: http://dx.doi.org/10.1007/s00018-014-1689-x, doi:10.1007/s00018-014-1689-x. This article has 292 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1007/s00018-014-1689-x)

[7. (Lee2010Extracellular) Se-Jin Lee. Extracellular regulation of myostatin: a molecular rheostat for muscle mass. Immunology‚ Endocrine &amp; Metabolic Agents in Medicinal Chemistry, 10(4):183–194, December 2010. URL: http://dx.doi.org/10.2174/187152210793663748, doi:10.2174/187152210793663748. This article has 74 citations.](https://doi.org/10.2174/187152210793663748)

[8. (Thomas2000Myostatin) Mark Thomas, Brett Langley, Carole Berry, Mridula Sharma, Sonnie Kirk, John Bass, and Ravi Kambadur. Myostatin, a negative regulator of muscle growth, functions by inhibiting myoblast proliferation. Journal of Biological Chemistry, 275(51):40235–40243, December 2000. URL: http://dx.doi.org/10.1074/jbc.m004356200, doi:10.1074/jbc.m004356200. This article has 743 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m004356200)

[9. (McPherron1997Double) Alexandra C. McPherron and Se-Jin Lee. Double muscling in cattle due to mutations in the myostatin gene. Proceedings of the National Academy of Sciences, 94(23):12457–12461, November 1997. URL: http://dx.doi.org/10.1073/pnas.94.23.12457, doi:10.1073/pnas.94.23.12457. This article has 1483 citations.](https://doi.org/10.1073/pnas.94.23.12457)

[10. (Wolfman2003Activation) Neil M. Wolfman, Alexandra C. McPherron, William N. Pappano, Monique V. Davies, Kening Song, Kathleen N. Tomkinson, Jill F. Wright, Liz Zhao, Suzanne M. Sebald, Daniel S. Greenspan, and Se-Jin Lee. Activation of latent myostatin by the bmp-1/tolloid family of metalloproteinases. Proceedings of the National Academy of Sciences, 100(26):15842–15846, December 2003. URL: http://dx.doi.org/10.1073/pnas.2534946100, doi:10.1073/pnas.2534946100. This article has 353 citations.](https://doi.org/10.1073/pnas.2534946100)

[11. (Singh2014Molecular) Satyendra Pal Singh, Priya Kumari, Rohit Kumar, Mamta Negi, Sanjeev Kumar Sharma, Manali Gangwar, Subodh Kumar, and Abhijit Mitra. Molecular characterization and phylogeny based analysis of complete coding sequence of myostatin (mstn) gene in indian goat breeds. Small Ruminant Research, 116(2–3):100–110, February 2014. URL: http://dx.doi.org/10.1016/j.smallrumres.2013.10.013, doi:10.1016/j.smallrumres.2013.10.013. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.smallrumres.2013.10.013)

[12. (Rı́os2002Myostatin) Ramón Rı́os, Isabel Carneiro, Víctor M. Arce, and Jesús Devesa. Myostatin is an inhibitor of myogenic differentiation. American Journal of Physiology-Cell Physiology, 282(5):C993–C999, May 2002. URL: http://dx.doi.org/10.1152/ajpcell.00372.2001, doi:10.1152/ajpcell.00372.2001. This article has 222 citations.](https://doi.org/10.1152/ajpcell.00372.2001)